Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.

[1]  L. Szekely,et al.  Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions , 2014, BMC Cancer.

[2]  Y. Ichinose,et al.  Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy , 2014, International Journal of Clinical Oncology.

[3]  G. Ceresoli,et al.  Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey , 2014, British Journal of Cancer.

[4]  G. Ceresoli,et al.  Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. , 2014, Lung cancer.

[5]  C. Sima,et al.  Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. , 2014, Lung cancer.

[6]  V. Torri,et al.  The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. , 2013, Critical reviews in oncology/hematology.

[7]  E. Santoni-Rugiu,et al.  Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  T. Gerds,et al.  A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma , 2012, Cancer Chemotherapy and Pharmacology.

[9]  H. Pass,et al.  BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma , 2012, The Journal of pathology.

[10]  R. Tumino,et al.  Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian National Register , 2012, International journal of cancer.

[11]  G. Ceresoli,et al.  Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. , 2012, Lung cancer.

[12]  T. Gerds,et al.  Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Eun‐Kee Park,et al.  Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. , 2011, Bulletin of the World Health Organization.

[14]  G. Ceresoli,et al.  Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. , 2011, Lung cancer.

[15]  V. Georgoulias,et al.  Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer , 2010, British Journal of Cancer.

[16]  G. Ceresoli,et al.  Second-line treatment for malignant pleural mesothelioma. , 2010, Cancer treatment reviews.

[17]  H. Dienemann,et al.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.

[18]  A. Santoro,et al.  Future developments in the management of malignant pleural mesothelioma , 2009, Expert review of anticancer therapy.

[19]  A. Bezjak,et al.  Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Allen D. Roses,et al.  Pharmacogenetics in drug discovery and development: a translational perspective , 2008, Nature Reviews Drug Discovery.

[21]  K. Nackaerts,et al.  Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  T. Palshof,et al.  Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma , 2008, British Journal of Cancer.

[23]  A. Nicholson,et al.  Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial , 2008, The Lancet.

[24]  F. Cappuzzo,et al.  Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma , 2008, Cancer.

[25]  M. Mencoboni,et al.  Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  C. Dumontet,et al.  Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? , 2008, The Lancet. Oncology.

[27]  D. Talbot,et al.  Phase II study of vinflunine in malignant pleural mesothelioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Pasquier,et al.  Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer , 2007 .

[29]  G. Bepler,et al.  RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Ceribelli,et al.  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Mackey,et al.  Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel , 2005, Molecular Cancer Therapeutics.

[32]  G. Giaccone,et al.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Dumontet,et al.  Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy , 2005, Clinical Cancer Research.

[34]  Y. Ichinose,et al.  Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. , 2005, Japanese journal of clinical oncology.

[35]  K. Nackaerts,et al.  Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  M. Kavallaris,et al.  Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. , 2005, Current pharmaceutical design.

[37]  J. Shamash,et al.  Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. , 2005, Lung cancer.

[38]  E. Felip,et al.  BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. , 2004, Human molecular genetics.

[39]  Susan Band Horwitz,et al.  Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.

[40]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[41]  U. Gatzemeier,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  C. Boland,et al.  BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells , 2003, British Journal of Cancer.

[43]  G. Scagliotti,et al.  Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Johnston,et al.  BRCA1: mechanisms of inactivation and implications for management of patients , 2002, The Lancet.

[45]  M. Lillo,et al.  Location and properties of the taxol binding center in microtubules: a picosecond laser study with fluorescent taxoids. , 2002, Biochemistry.

[46]  B. Sjöberg,et al.  The Evolution of the Ribonucleotide Reductases: Much Ado About Oxygen , 2002, Journal of Molecular Evolution.

[47]  E. Liu,et al.  BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents , 2001, Oncogene.

[48]  J. Shamash,et al.  Phase II study of vinorelbine in patients with malignant pleural mesothelioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  F. Colpaert,et al.  Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. , 1999, European journal of cancer.

[50]  B. Sikic,et al.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  T. Hickish,et al.  Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  J. de Haes,et al.  Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. , 1990, British Journal of Cancer.

[53]  R. Rahmani,et al.  Preclinical and Clinical Pharmacology of Vinca Alkaloids , 2012, Drugs.

[54]  J. Sørensen,et al.  Second-line Oral Vinorelbine Following First-Line Platinum and Pemetrexed in Malignant Pleural Mesothelioma , 2012 .

[55]  T. Powles,et al.  The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. , 2009, Lung cancer.

[56]  G. Giaccone,et al.  Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.